Progress of neoadjuvant immunotherapy in the treatment of locally advanced resectable esophageal carcinoma

Junjun Huang; Jiuhe Sun; Shifa Zhang; Hongfeng Liu; Ru Song; Qian Wang; Liji Chen; Haibo Cai

Return

Progress of neoadjuvant immunotherapy in the treatment of locally advanced resectable esophageal carcinoma

VernacularTitle:局部晚期可切除食管癌新辅助免疫治疗进展
Author: Junjun HUANG ¹ ; Jiuhe SUN ^{2
,

3} ; Shifa ZHANG ^{2
,

3} ; Hongfeng LIU ^{2
,

3} ; Ru SONG ^{2
,

3} ; Qian WANG ¹ ; Liji CHEN ¹ ; Haibo CAI ^{2
,

3}
Author Information

1. Clinical Medical School of Jining, Jining, 272000, Shandong, P. R. China
2. Department of Thoracic Surgery, Jining No.1 People'
3. s Hospital, Jining, 272000, Shandong, P. R. China
Publication Type:Journal Article
Keywords: Neoadjuvant immunotherapy; locally advanced resectable esophageal carcinoma; review
From: Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2024;31(07):1058-1065
CountryChina
Language:Chinese
Abstract: Surgery is the preferred treatment for resectable esophageal cancer, but in locally advanced esophageal cancer, the effect of surgery alone is not ideal, so surgery-based comprehensive treatment is the best option. Neoadjuvant therapy has become a standard treatment in the treatment of locally advanced resectable esophageal cancer. Neoadjuvant therapy includes neoadjuvant chemotherapy, radiochemotherapy, immunotherapy, targeted therapy, etc. With the significant efficacy and acceptable toxicity of immunotherapy in the first-line and second-line treatment of advanced esophageal cancer, neoadjuvant immunotherapy has become a research hotspot of locally advanced resectable esophageal cancer. This article reviews the latest research progress and some limitations of neoadjuvant immunotherapy in locally advanced resectable esophageal cancer.